Business Wire

Wipro’s Third Annual State of Cybersecurity Report Finds Organizations Focusing on IoT and Cloud While Developing Cyber Defense Systems

6.8.2019 15:49:00 EEST | Business Wire | Press release

Share

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today released its 2019 State of Cybersecurity Report that highlights the rising importance of cybersecurity defense to global leaders, the emergence of the CISO as a C-Suite role, and an unprecedented focus on security as a pervasive part of the business operations.

The study found that one in five CISOs are now reporting directly to the CEO, 15% of organizations have a security budget of more than 10% of their overall IT budgets, 65% of organizations are tracking and reporting regulatory compliance, and 25% of organizations are carrying out security assessments in every build cycle. In addition, 39% of organizations now have a dedicated cyber insurance policy. All of these points showed dramatic increases from previous years.

The annual study is based on three months of primary and secondary research, including surveys of security leadership, operational analysts, and 211 global organizations across 27 countries.

Additional highlights from the report:

  1. More data exposed, yet a decline in the number of publicly disclosed breaches. While the number of significant publicly reported breaches decreased by 25%, the number of records exposed during attacks increased by 164% to 232 records exposed per second. Attackers also targeted more specific information perceived to have higher monetary value: 38% of the data records breached/targeted were a combination of personally identifiable information and security credentials such as passwords.
  2. Cryptominers are the new big threat. Cryptominer malware surged to become the new emerging threat: 25% of global organizations were targeted by Coinhive malware alone in 2018. 80% of all cryptomining attacks originated from just three sources: Coinhive, Cryptoloot, and JSEcoin. Ransomware attacks by contrast declined in 2018.

Yet organizations are aligning themselves to cyber-resilient strategies in new ways:

  1. Cloud and IoT security strategies on the radar. With cloud and IoT adoption on the rise, 28% of organizations perceive cloud account hijacking as one of the top security threats to their cloud environments. 26% of organizations are prioritizing security assessment of IoT devices to mitigate new risks.
  2. Collective wisdom trumps learning in isolation: 67% of organizations are now willing to share indicators of compromise (malicious IPs, URLs, domains), and 33% of organizations are willing to share attacker tactics, techniques, and procedures with industry peers. Information sharing and timely threat intelligence have become critical enablers in anticipating and mitigating new and developing attacks.
  3. More pervasive approach to protection. 39% of organizations now have a dedicated cyber insurance policy, up by 12% from 2017; 28% of organizations participate in cyberattack simulation exercises coordinated by industry regulators; and 1 in 4 organizations now carry out security assessments in every build cycle.

Raja Ukil, Global Head for Cybersecurity & Risk Services, Wipro Limited said, “With organizations riding the digital wave, security strategies need to be enhanced to address the changing landscape and enable a smooth and safe transition. Security is also evolving to be a pervasive part of core business operations, and countries are establishing active cyber defense strategies and functions to foster partnerships with the private sector enterprises and with other countries. Amidst growing threats, leaders are collaborating more than ever before in new and innovative ways to mitigate the risks.”

Wipro’s in-depth report demystifies the forces that have shaped the environmental conditions of this battleground and provides needed insight into the future of cybersecurity.

The full report can be found here [ https://www.wipro.com/applications/form/the-state-of-cybersecurity-report-2019 ].

About Wipro Limited

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 175,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future.

Forward-looking and Cautionary Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property, and general economic conditions affecting our business and industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Purnima Burman
Wipro Limited
purnima.burman@wipro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release

Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye